OVID THERAPEUTICS INC.
Ownership & governance
Executives 5Directors 8Avg age 62Avg tenure 5y
MA
Margaret Alexander
Chief Executive Officer
Age 45Since 2025-12-31Profile →
+12
Executives5
MA
Margaret Alexander→
Chief Executive Officer
Age 45Since 2025-12-31
JR
Jeffrey Rona→
Director of Finance/CFO
Age 57Since 2021-06-01
PK
Petra Kaufmann→
Chief Tech/Sci/R&D Officer
Age 60Since 2025-12-01
ZZ
Zhong Zhong→
Chief Tech/Sci/R&D Officer
—Since 2023-06-27
JT
Julia Tsai→
Chief Tech/Sci/R&D Officer
—Since 2021-07-07
Board of directors8
JL
Jeremy Levin→
Chairman
Age 72Since 2014-03-31
KB
Karen Bernstein→
Director/Board Member
Age 73Since 2015-09-29
BF
Bart Friedman→
Director/Board Member
Age 81Since 2015-11-22
BD
Barbara Duncan→
Director/Board Member
Age 61Since 2017-06-13
KF
Kevin Fitzgerald→
Director/Board Member
Age 58Since 2021-10-05
MA
Margaret Alexander→
Director/Board Member
Age 45Since 2025-12-31
SP
Stelios Papadopoulos→
Director/Board Member
Age 77Since 2025-03-02
AG
Anna Greka→
Director/Board Member
Age 50Since 2026-06-14
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Janus Henderson Investors US LLC | 5.74 % | 10,714,000 |
| RA Capital Management LP | 5.74 % | 10,714,000 |
| Affinity Asset Advisors LLC | 5.699 % | 10,636,318 |
| Eventide Asset Management LLC | 5.313 % | 9,916,911 |
| Sirenia Capital Management LP | 5.079 % | 9,479,000 |
Catalog · 2026-07-09
SEC officers14
| Name | Role | Since | Shares |
|---|---|---|---|
| Charles Carter | Chief Financial Officer | — | - |
| Jeffrey Rona | Director of Finance/CFO | — | - |
| Jeremy Levin | Chairman | — | - |
| Julia Tsai | Chief Tech/Sci/R&D Officer | — | - |
| Margaret Alexander | Chief Executive Officer | — | - |
| Petra Kaufmann | Chief Tech/Sci/R&D Officer | — | - |
| Zhong Zhong | Chief Tech/Sci/R&D Officer | — | - |
| Anna Greka | Director/Board Member | — | - |
SEC · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 6.11Range 4–9Analysts 9
4Mean 6.119
- Buy 12
Broker actions40 of 53
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Wolfe Research | Initiated | Outperform | 5 | 2026-10-15 |
| Cantor Fitzgerald | Initiated | Overweight | — | 2026-10-09 |
| Guggenheim | Initiated | Buy | 7 | 2026-10-06 |
| Guggenheim | Initiated | Buy | 7 | 2026-10-05 |
| HC Wainwright & Co. | Maintained | Buy | 5 | 2026-09-11 |
| Oppenheimer | Maintained | Outperform | 9 | 2026-08-03 |
| Wedbush | Reiterated | Outperform | 7 | 2026-04-15 |
| HC Wainwright & Co. | Maintained | Buy | 4 | 2026-04-09 |
| BTIG | Reiterated | Buy | 4 | 2026-03-26 |
| Wedbush | Maintained | Outperform | 7 | 2026-03-20 |
| LifeSci Capital | Initiated | Outperform | 4 | 2025-12-22 |
| HC Wainwright & Co. | Reiterated | Buy | 2 | 2025-12-22 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.